The story of BioDuro over these nearly three decades begins with a son sitting at his mother's bedside, realizing that medicine moves too slowly when the person you love is running out of time. It was there, in the helpless rhythm of hospital monitors, that Dr. Masood Tayebi made himself a quiet promise: if patients must wait, he would devote his life to making that wait shorter.

Masood was not a chemist or a physician; he built wireless networks, not molecules. Yet, as he searched for treatments for his mother’s lung cancer, speaking to scientists, evaluating options, grasping for anything that might help, he saw something that would change his life. Behind every new therapy were years of delay, scattered efforts, and families living from one hopeful headline to the next, asking the same question: "Is something new coming?"    

The realization was painfully simple: patients were always waiting, and the system that could help them was too slow. So, Masood reframed his grief into a mission - to build a company that could help discover drugs faster and more efficiently, because patients and their families could not afford to wait.    

When he first explored where to build this new kind of company, Masood looked across three major innovation hubs: the United States, India, and China. Each offered strong science and talent, but China stood out for how strongly its ecosystem leaned into possibility.

In China, he encountered a very different attitude: not a culture of "no," but a culture of "yes, let’s try." Government officials would meet Masood on a Sunday because drug discovery mattered. University leaders who opened their doors and their labs, eager to show him the depth of talent in chemistry, biology, and pharmacology, and determined to build something meaningful together.

For Masood, this alignment of diligence, openness, and scientific ambition was more than attractive; it was a signal. If he wanted to build a company that moved at the speed of patients' needs, this was the environment where it could happen.

Coming from telecom, Masood was familiar with complex systems that worked only when all the pieces were connected - planning, design, build, and manage forming a continuous loop. Looking at drug discovery, he saw the same pattern: a long, fragmented journey where molecules traveled from one company to another, one country to another, adding time and cost at every handoff.

He asked a simple but radical question: what if we did it all together? Not "just chemistry" or "just biology," but truly integrated drug discovery, making compounds, running assays, doing in vitro and animal studies under one roof, with one team, one mindset, and one shared urgency. BioDuro became one of the first companies to embrace and name this model, not as a marketing term, but as a design principle: if patients are waiting, every avoidable delay is unacceptable.

This approach began to change timelines in a very real way. Projects that once took five to seven years to reach key regulatory filings started reaching that point in two to three years, and often closer to two and a half years. Integrated drug discovery was not a slogan; it was a concrete answer to the question Masood first asked in that hospital room: "How can we move faster for patients?"

From the beginning, Masood's vision for BioDuro refused to recognize borders - scientific, cultural, or political. Registered and rooted in San Diego, the company operated as a bridge between continents: scientific leaders from the US, and China working side by side, flying back and forth, sharing expertise, and building something larger than any one site or nationality.

This worldview was shaped not only by business but by Masood's faith, which emphasizes open borders, equality, and the oneness of humanity. Science, he often says, has no passport; patients have no borders. Politics may ebb and flow with each election cycle, but the work of solving disease spans lifetimes and generations.

As the biopharmaceutical landscape shifted and geopolitical rhetoric sometimes cast shadows over cross‑border collaboration, BioDuro kept anchoring itself in a different truth: the industry will always go where the best science is, and the best science comes from diverse minds working together.

Inside its walls, BioDuro was never meant to feel like a machine; it was meant to feel like a family. From day one, Masood and his leadership team set out to build a culture where people felt seen, valued, and proud - not just of the projects they delivered, but of the difference their work made. Over time, employees started calling it "the happy company," a nickname that stuck because it felt true.

Masood noticed something else: scientists and medical professionals often looked younger than their years. He liked to joke that it was because they were doing what they loved, but beneath the joke was deep respect. In his eyes, few careers demand as much persistence in the face of failure as science, and yet scientists keep going because their work is tethered to human lives. To them and to the CEOs and leaders they collaborate with, Masood’s message is simple: thank you for being who you are, for shouldering the heartaches and uncertainties to push the world forward.

Over the past decades, Masood reflected that BioDuro has touched thousands of drug programs, helping hundreds of them succeed and move forward toward patients. Somewhere in the world today, there are millions of people whose treatments trace back, in some quiet way, to molecules that passed through BioDuro's labs. For Masood, that is not an abstract metric; it is the realization of the promise he made to his mother: to help patients like her get access to better therapies, faster.

The company's impact doesn’t end with molecules or milestones. Over the years, hundreds of former BioDuro colleagues have gone on to find their own companies, many of which later returned as BioDuro clients. The ecosystem is now self‑reinforcing: a generation trained in integrated, patient‑first science spins out, builds new ventures, and then comes back to collaborate, carrying BioDuro's values into the broader industry.

When it came to the time to choose a symbol, Masood chose the oak tree: a tree of life, durability, and deep roots. "Duro" for durability, the oak for lasting life, the image of a company designed not for a quick exit, but to stand for generations. Today, that oak has grown far beyond what he imagined in those early trips to Shanghai, Beijing, and San Diego office parks.

The brand is recognized across continents. Its roots have spread through employees, partners, alumni, and patients; its branches now touch Australia, Asia, Europe, and the United States. Politics will change, business cycles will rise and fall, but the need to make people’s lives better and to solve diseases faster will not.

As BioDuro enters its new decade, the dream is both simple and ambitious: to keep doing what it was born to do, on a larger and deeper scale. To remain at the center of global drug discovery, not just as a service provider, but as a trusted partner that helps ideas become therapies with less waiting in between.

For the people of BioDuro, this anniversary is not just a corporate milestone. It is a reminder that every molecule, every assay, every formulation, every carefully documented result is part of a much bigger story: the story of a son's promise, a company built around patients, and a global family that believes science has no borders and that the wait for hope should always be as short as possible.